EGFR and non-small cell lung carcinoma: Furthermore, first‐ and second‐generation EGFR‐TKIs are prominently used in several cancer care settings—therefore, it remains a matter of urgency to be able to accurately and sensitively recognize the presence of p.T790 M in NSCLC patients treated with these targeted therapies, at the earliest possible time point.